What are the targets of cabozantinib? Analysis of mechanism of action and scope of influence

Cabozantinib is a multi-target targeted therapy drug that is widely used to treat a variety of cancers, including renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, etc. It exerts anti-cancer effects by inhibiting a variety of signaling pathways related to tumor growth and metastasis. The following is an analysis of the main targets and mechanism of action of cabozantinib:

1. Targeting receptor tyrosine kinases: One of the main mechanisms of action of cabozantinib is to interfere with the growth and spread of tumor cells by inhibiting receptor tyrosine kinases (RTKs). It can inhibit, for example, MET (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), AXL (receptor tyrosine kinaseAxl), RET (proto-oncogeneRET) and other key receptors. MET and VEGFR2 are closely related to the proliferation, angiogenesis and metastasis of tumor cells. Cabozantinib can effectively prevent tumor growth and angiogenesis by inhibiting the activation of these receptors, thereby inhibiting tumor metastasis and recurrence.

2. Affects the tumor microenvironment: Cabozantinib not only affects the growth of tumor cells, but also inhibits tumor progression by regulating the tumor microenvironment. It reduces the formation of new blood vessels by inhibiting the VEGF/VEGFR pathway, thereby limiting the blood supply and oxygen supply to tumors. This vasoinhibitory effect prevents tumor cells from receiving sufficient nutrients and oxygen, thereby inhibiting tumor growth. Through this mechanism, cabozantinib can significantly reduce tumor invasion and metastasis, which is especially important for patients with advanced or metastatic tumors.

3. Inhibit the invasiveness of tumor cells: In addition to targeting tyrosine kinases, cabozantinib can also reduce the invasive ability of tumor cells by inhibiting pathways related to tumor invasiveness and metastasis, such as MET, AXL, etc. Studies have shown that cabozantinib can inhibit the growth and spread of tumor cells in the blood, especially in patients with metastatic tumors, and can significantly reduce the risk of tumor expansion and metastasis.

4. Influence immune response: The latest research also found that cabozantinib also has a certain regulatory effect on the tumor immune microenvironment. It may be through inhibitionTAM (tumor-associated macrophages) and regulate immune cell responses to enhance the immune system's attack on tumors. Although the immunomodulatory effect of cabozantinib is still in the research stage, existing evidence shows that it may have the potential to improve the efficacy of immune checkpoint inhibitors, further enhancing its application prospects in tumor immunotherapy.

In summary, cabozantinib can effectively inhibit tumor growth and metastasis through a multi-target mechanism of action, including inhibiting key receptor tyrosine kinases, reducing angiogenesis, reducing tumor cell invasiveness and regulating immune responses, and provides treatment options for patients with various types of cancer.

Reference:https://en.wikipedia.org/wiki/Cabozantinib